The demand of an item sold during a short period of the year is always difficult to anticipate, particularly if the manufacturing process is long, and if the possible overproduction is not salable the following year, which is the case of flu vaccines evolving every year.
From a business point of view, the problem is not greed at this stage, it is to find a way to cover the risk of overproduction; the cost of this risk must be included in the final price paid by the end user (directly, or indirectly if the governement manages it).
From a business point of view, the problem is not greed at this stage, it is to find a way to cover the risk of overproduction; the cost of this risk must be included in the final price paid by the end user (directly, or indirectly if the governement manages it).
. Mordoch has richly pointed out that is a red herring. Her effects on the flu vaccines are minimal. What you haven't discussed are the issues involved, namely a mature industry, razor thin profit margins, long lead in production without any ability to react to increased demand, and a heavy profit penalty for over-production.
) pay an increased tax for.
Comment